Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACHV Achieve Life Sciences	$3.51 -7.6%	$3.03	$1.84 ▼ $5.31	$131.80M	1.63	205,859 shs	576,740 shs
ACTU Actuate Therapeutics	$5.82 -9.6%	$9.18	$5.51 ▼ $11.99	$126.35M	N/A	51,783 shs	77,013 shs
FATE Fate Therapeutics	$1.10 -5.2%	$1.23	$0.66 ▼ $5.92	$132.94M	2.23	2.20 million shs	1.98 million shs
SHLT SHL Telemedicine	$2.05	$2.05	$1.85 ▼ $5.10	$33.61M	0.11	11,182 shs	N/A

Elon Musk's Next Move

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACHV Achieve Life Sciences	-7.63%	+11.78%	+11.08%	+26.26%	-26.26%
ACTU Actuate Therapeutics	-9.63%	-22.30%	-43.55%	-26.33%	+581,999,900.00%
FATE Fate Therapeutics	-5.17%	-9.09%	-9.84%	+29.52%	-66.26%
SHLT SHL Telemedicine	0.00%	0.00%	0.00%	-2.15%	-61.17%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ACHV Achieve Life Sciences	1.8731 of 5 stars	3.8	1.0	0.0	0.0	2.6	0.0	0.6
ACTU Actuate Therapeutics	1.994 of 5 stars	3.5	0.0	0.0	0.0	2.7	1.7	0.0
FATE Fate Therapeutics	4.1062 of 5 stars	3.1	3.0	0.0	4.7	2.6	1.7	0.6
SHLT SHL Telemedicine	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACHV Achieve Life Sciences	3.50	Strong Buy	$14.33	308.36% Upside
ACTU Actuate Therapeutics	3.00	Buy	$20.50	252.23% Upside
FATE Fate Therapeutics	2.13	Hold	$3.83	248.48% Upside
SHLT SHL Telemedicine	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest SHLT, FATE, ACTU, and ACHV Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/12/2025	FATE Fate Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold ➝ Hold
6/3/2025	ACTU Actuate Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy	$20.00
5/14/2025	FATE Fate Therapeutics	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$10.00 ➝ $2.00
5/14/2025	FATE Fate Therapeutics	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$5.00 ➝ $4.00
5/14/2025	FATE Fate Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold ➝ Hold
4/22/2025	ACTU Actuate Therapeutics	Craig Hallum Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$21.00

(Data available from 6/27/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACHV Achieve Life Sciences	N/A	N/A	N/A	N/A	$0.61 per share	N/A
ACTU Actuate Therapeutics	N/A	N/A	N/A	N/A	$0.01 per share	N/A
FATE Fate Therapeutics	$13.63M	9.25	N/A	N/A	$2.80 per share	0.39
SHLT SHL Telemedicine	$55.94M	0.60	$0.04 per share	54.03	$5.21 per share	0.39

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACHV Achieve Life Sciences	-$39.83M	-$1.34	N/A	N/A	N/A	N/A	-176.11%	-103.32%	8/12/2025 (Estimated)
ACTU Actuate Therapeutics	-$27.28M	N/A	0.00	∞	N/A	N/A	N/A	-339.73%	N/A
FATE Fate Therapeutics	-$186.26M	-$1.49	N/A	N/A	N/A	-1,318.93%	-47.17%	-34.60%	8/12/2025 (Estimated)
SHLT SHL Telemedicine	-$7.06M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A

Latest SHLT, FATE, ACTU, and ACHV Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/15/2025	Q1 2025	ACTU Actuate Therapeutics	-$0.26	-$0.32	-$0.06	-$0.32	N/A	N/A
5/13/2025	Q1 2025	ACHV Achieve Life Sciences	-$0.37	-$0.37	N/A	-$0.37	N/A	N/A
5/13/2025	Q1 2025	FATE Fate Therapeutics	-$0.39	-$0.32	+$0.07	-$0.32	$1.18 million	$1.63 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACHV Achieve Life Sciences	N/A	N/A	N/A	N/A	N/A
ACTU Actuate Therapeutics	N/A	N/A	N/A	N/A	N/A
FATE Fate Therapeutics	N/A	N/A	N/A	N/A	N/A
SHLT SHL Telemedicine	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACHV Achieve Life Sciences	0.85	3.51	3.51
ACTU Actuate Therapeutics	N/A	0.46	0.46
FATE Fate Therapeutics	N/A	8.81	8.81
SHLT SHL Telemedicine	0.19	2.17	1.98

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACHV Achieve Life Sciences	33.52%
ACTU Actuate Therapeutics	N/A
FATE Fate Therapeutics	97.54%
SHLT SHL Telemedicine	20.11%

Insider Ownership

Company	Insider Ownership
ACHV Achieve Life Sciences	3.00%
ACTU Actuate Therapeutics	69.34%
FATE Fate Therapeutics	5.51%
SHLT SHL Telemedicine	N/A

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACHV Achieve Life Sciences	20	34.69 million	33.64 million	Optionable
ACTU Actuate Therapeutics	10	19.62 million	6.02 million	N/A
FATE Fate Therapeutics	550	114.60 million	108.29 million	Optionable
SHLT SHL Telemedicine	583	16.39 million	N/A	Not Optionable

SHLT, FATE, ACTU, and ACHV Headlines

Recent News About These Companies

SHL Telemedicine ADR Stock Price History

June 20, 2025 | investing.com

SHL Telemedicine Clarifies Voting Process for May 2025 AGM

May 20, 2025 | tipranks.com

SHL Telemedicine to Delist ADRs from Nasdaq to Cut Costs

March 11, 2025 | tipranks.com

SHLT SHL Telemedicine Ltd.

March 6, 2025 | seekingalpha.com

SHL Telemedicine Ltd (SHLTN)

January 23, 2025 | investing.com

SHL Telemedicine (NASDAQ:SHLT) Stock Quotes, Forecast and News Summary

December 18, 2024 | benzinga.com

DocGo and SHL Telemedicine Partner to Revolutionize Patient Access to Cardiovascular Care

December 18, 2024 | businesswire.com

SHL Telemedicine (NASDAQ:SHLT) Stock, Short Interest Report

October 9, 2024 | benzinga.com

SHL Telemedicine to Appoint David Arnon as CEO of SHL Telemedicine

July 29, 2024 | 01net.it0

SHL Telemedicine Confirms Discussions Regarding a Possible Investment in its Israeli Activity

June 20, 2024 | businesswire.com

SHL Telemedicine Expands Offering in Israel With Groundbreaking At-home Biomarker Blood Test

May 21, 2024 | businesswire.com

SHL Telemedicine Ltd ADR - New

May 17, 2024 | morningstar.comM

SHL Telemedicine Announces Official Launch of SmartHeart® D2C Membership in the US Following Successful Soft Launch

May 16, 2024 | finance.yahoo.com

SHL Telemedicine Announces Official Launch of SmartHeart® D2C Membership in the US Following Successful Soft Launch

May 16, 2024 | businesswire.com

SHL Telemedicine Ltd.: SHL Announces Full-Year 2023 Results - Stable Revenue Growth Alongside Groundbreaking Clinical Milestones

April 17, 2024 | finanznachrichten.de

SHL Announces Full-Year 2023 Results - Stable Revenue Growth Alongside Groundbreaking Clinical Milestones

April 17, 2024 | finance.yahoo.com

SHL Telemedicine Ltd. (SHLT)

April 16, 2024 | finance.yahoo.com

Telehealth clinical trial cuts hospital cardiac readmissions by 76%

April 11, 2024 | msn.com

Imperial College London Study Shows Groundbreaking Final Results for SHL Telemedicine’s SmartHeart® in Post-ACS Patient Care

April 11, 2024 | finance.yahoo.com

Imperial College London Study Shows Groundbreaking Final Results for SHL Telemedicine's SmartHeart® in Post-ACS Patient Care

April 11, 2024 | businesswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

In a Historic Shift, 2 Cybersecurity Stocks Plan to Buyback Stock
By Leo Miller | June 9, 2025
View In a Historic Shift, 2 Cybersecurity Stocks Plan to Buyback Stock
Toyota Supercharges Joby: $250M Capital Infusion Ignites Stock
By Jeffrey Neal Johnson | May 28, 2025
View Toyota Supercharges Joby: $250M Capital Infusion Ignites Stock
Micron Joins Latest $200 Billion United States Investment
By Gabriel Osorio-Mazilli | June 16, 2025
View Micron Joins Latest $200 Billion United States Investment
Constellation Energy and Meta Strike Nuclear Deal, Shares Whipsaw
By Leo Miller | June 4, 2025
View Constellation Energy and Meta Strike Nuclear Deal, Shares Whipsaw
Tesla Stock: Why These 2 Downgrades Are Actually a Buy Signal
By Sam Quirke | June 11, 2025
View Tesla Stock: Why These 2 Downgrades Are Actually a Buy Signal

SHLT, FATE, ACTU, and ACHV Company Descriptions

Achieve Life Sciences NASDAQ:ACHV

$3.51 -0.29 (-7.63%)

Closing price 06/26/2025 04:00 PM Eastern

Extended Trading

$2.96 -0.56 (-15.81%)

As of 04:32 AM Eastern

Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes cytisinicline for smoking cessation and nicotine addiction. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms. It has license and supply agreement with Sopharma AD and University of Bristol Achieve Life Sciences, Inc. is based in Vancouver, Canada.

Actuate Therapeutics NASDAQ:ACTU

$5.82 -0.62 (-9.63%)

Closing price 06/26/2025 04:00 PM Eastern

Extended Trading

$6.93 +1.11 (+19.07%)

As of 04:43 AM Eastern

Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of cancers. The company's lead product candidate is Elraglusib Injection, a novel glycogen synthase kinase-3 inhibitor to treat metastatic pancreatic ductal adenocarcinoma. It also develops Elraglusib for the treatment of Ewing sarcoma, metastatic melanoma, and colorectal cancer. The company was formerly known as Apotheca Therapeutics, Inc. and changed its name to Actuate Therapeutics, Inc. in October 2015. The company was incorporated in 2015 and is based in Fort Worth, Texas.

Fate Therapeutics NASDAQ:FATE

$1.10 -0.06 (-5.17%)

Closing price 06/26/2025 04:00 PM Eastern

Extended Trading

$1.10 +0.00 (+0.36%)

As of 04:39 AM Eastern

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.

SHL Telemedicine NASDAQ:SHLT

$2.05 0.00 (0.00%)

As of 04/16/2025

SHL Telemedicine Ltd., together with its subsidiaries, develops and markets personal telemedicine solutions in Israel, Europe, and internationally. It offers smartheart, a personal mobile 12 lead ECG device that enables the detection of heart attacks; CardioSen'C, a personal cellular-digital 12-lead ECG transmitter device; and Cardio'B, a portable device to transmit a 12-lead ECG. The company also provides central communication module, a telecommunication device that transmits medical data to its telemedicine centers from various medical monitoring devices, including blood pressure, weighing, oxygen saturation level (TelePulse Oximeter), breath exhalation (TeleBreather), and sugar measuring devices; and TelePress, a remote blood pressure monitoring device for personal use. It offers its telemedicine services and devices to subscribers using electronic and telecommunication technologies. The company serves physicians, hospitals, health insurance funds, and patients. It has a collaboration agreement with Mayo Clinic to evaluate the incidence of emergency department visits, re-hospitalizations, and major adverse cardiovascular events over a period of 90 days after first hospitalization for a heart attack for patients using SmartHeart FDA approved 12 lead ECG; and the Hebrew University of Jerusalem and the Hadassah Medical Center. The company was incorporated in 1986 and is headquartered in Tel Aviv, Israel.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time